The key dates for KRAS watch­ers through the end of the year — the trail is nar­row and risks are ex­treme

There’s noth­ing quite like a big patent win when it comes to bur­nish­ing your prospects in the pipeline. And for Am­gen, which seems to have res­cued En­brel for a run to 2029, the cheer­ing sec­tion on Wall Street is now fixed on AMG 510 and a key ri­val.

And it didn’t take much da­ta to do it. 

There was the first snap­shot of a hand­ful of pa­tients, with a 50% re­sponse rate. Then came word that Am­gen re­searchers are al­so track­ing re­spons­es in dif­fer­ent can­cers, at least one in col­orec­tal can­cer and ap­pen­diceal too. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER